Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer. A technique to reduce morbidity

被引:0
|
作者
Aufderklamm, S. [1 ]
Todenhoefer, T. [1 ]
Hennenlotter, J. [1 ]
Gakis, G. [1 ]
Mischinger, J. [1 ]
Mundhenk, J. [1 ]
Germann, M. [1 ]
Stenzl, A. [1 ]
Schwentner, C. [1 ]
机构
[1] Univ Tubingen, Urol Klin, D-72076 Tubingen, Germany
来源
UROLOGE | 2013年 / 52卷 / 08期
关键词
Testicular cancer; Morbidity; operative; Space-occupying lesion; persisting; Chemotherapy; platinum-based; Resection; bilateral; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; STAGE-I; TUMOR; LYMPHADENECTOMY; COMPLICATIONS; METASTASES;
D O I
10.1007/s00120-013-3133-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Retroperitoneal lymph node dissection (RPLND) is the most appropriate method for the detection of residual tumor tissue and mature teratoma after chemotherapy in patients with advanced nonseminomatous (NSGCT) or seminomatous (SGCT) germ cell tumors in clinical stage II-III. Open surgical procedures are associated with higher morbidity rates and laparoscopic RPLND offers a minimally invasive procedure with equivalent oncological safety and low morbidity. In 39 patients laparoscopic RPLND (L-RPLND) after platinum-based chemotherapy for clinical stage IIa-III NSGCT was performed unilaterally as well as bilaterally by two surgeons. Patients with retroperitoneal residual tumor > 1 cm and normalization of tumor markers after chemotherapy were included. Bilateral L-RPLND was performed with complete contralateral nerve sparing while the decision for ipsilateral nerve preservation was based on the volume of the residual mass in the respective standard field. The L-RPLND was completed in all patients without conversion. Median operation time was 248 min (range 95-397 min) and mean hospitalization time was 5 days (range 3-14 days). Furthermore, there was no difference in recurrence rate of the disease (p=0.45) between patients with unilateral or bilateral dissection. The postoperative ejaculatory function was normal in 37 out of 39 patients. The median follow-up period was 18.5 months (range 3-38 months) and 3 out of 39 patients developed recurrence (7.69 %). Post-chemotherapy L-RPLND is feasible with a lower complication rate and an adequate oncological safety and functional outcome. Due to the complexity of L-RPLND the procedure remains limited to institutions with extensive laparoscopic experience.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 50 条
  • [41] Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?
    Overs, C.
    Beauval, J. B.
    Mourey, L.
    Rischmann, P.
    Soulie, M.
    Roumiguie, M.
    Doumerc, Nicolas
    WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 655 - 661
  • [42] Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: Feasibility and outcomes of initial cases
    Islamoglu, Ekrem
    Ozsoy, Cagatay
    Anil, Hakan
    Aktas, Yasin
    Ates, Mutlu
    Savas, Murat
    TURKISH JOURNAL OF UROLOGY, 2019, 45 (02): : 113 - 117
  • [43] Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique
    Stepanian, Sevan
    Patel, Mayank
    Porter, James
    EUROPEAN UROLOGY, 2016, 70 (04) : 661 - 667
  • [44] Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes
    Nicolas Branger
    Franck Bladou
    Gregory Verhoest
    Sophie Knipper
    Grégoire Robert
    Jean-Christophe Bernhard
    Jean-Baptiste Beauval
    Abderrahmane Khaddad
    Anne Mauger De Varennes
    Aude Fléchon
    Jochen Walz
    Anne-Sophie Bageot
    Nicolas Doumerc
    Morgan Rouprêt
    Thibault Murez
    World Journal of Urology, 2023, 41 : 2405 - 2411
  • [45] Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting
    Considine, S.
    Heaney, R.
    Conroy, R.
    Thornhill, J. A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 (04) : 901 - 907
  • [46] Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: a focus beyond ejaculation disorders
    Dimitropoulos, K.
    Karatzas, A.
    Papandreou, C.
    Daliani, D.
    Zachos, I.
    Pisters, L. L.
    Tzortzis, V.
    ANDROLOGIA, 2016, 48 (04) : 425 - 430
  • [47] Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor: A tertiary care experience
    Franzese, Dario
    Tufano, Antonio
    Izzo, Alessandro
    Muscariello, Raffaele
    Grimaldi, Giovanni
    Quarto, Giuseppe
    Castaldo, Luigi
    Rossetti, Sabrina
    Pandolfo, Savio Domenico
    Desicato, Sonia
    Del Prete, Paola
    Ferro, Matteo
    Pignata, Sandro
    Perdona, Sisto
    ASIAN JOURNAL OF UROLOGY, 2023, 10 (04) : 440 - 445
  • [48] Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors
    Heidenreich, Axel
    Paffenholz, Pia
    Nestler, Tim
    Pfister, David
    Daneshmand, Siamak
    CURRENT OPINION IN UROLOGY, 2020, 30 (02) : 251 - 257
  • [49] Clinical and Pathological Features Predictive of Nephrectomy at Post-Chemotherapy Retroperitoneal Lymph Node Dissection
    Cary, K. Clint
    Beck, Stephen D. W.
    Bihrle, Richard
    Foster, Richard S.
    JOURNAL OF UROLOGY, 2013, 189 (03) : 812 - 817
  • [50] Laparoscopic Retroperitoneal Lymph Node Dissection as a Safe Procedure for Postchemotherapy Residual Mass in Testicular Cancer
    Faria, Eliney Ferreira
    Neves, Hugo Silva
    Dauster, Breno
    Machado, Roberto Dias
    Magnabosco, Wesley Justino
    Muller, Roberto Lodeiro
    Santos, Alexandre Cesar
    Tobias-Machado, Marcos
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2018, 28 (02): : 168 - 173